Acomplia trials

The Royal Perth Hospital study,as a part of an international trial, is on the way to prove that the new weight-loss pill rimonabant, sold as Acomplia, will help to heal obesity which entails problems controlling blood pressure, cholesterol and insulin. Acomplia also should help people to stop smoking.

Rimonabant acomplia should be approved for Australia within a next few months. Perth hospital recruied 20 patients as part of the 80 being studied worldwide. Men and women aged 35 to 65 who are overweight or obese with a waist circumference of more than 88cm in women and 102cm in men and have high triglycerides with low HDL cholesterol.

As RPH professor of medicine Gerald Watts said: “We’re interested in the mechanism of how this drug works and the role it could play in obese people who have several risk factors for heart disease, one of which is low HDL cholesterol, or metabolic syndrome,� he said.

“The drugs that have been available until now have had toxic effects and some work but have no long-term safety data, so this is a new approach to the management of obesity.�

The Rimonabant acomplia is famous by blocking chemical processes directly in the brain Results are: reduced appetite, help liver to burn more fat and it might be effective drug for curbing smoking and even alcohol abuse. Company Sanofi - producer of Rimonabant Acomplia is already on the market in Europe, being sold under the trade name Acomplia, and is awaiting approval in the United States.



Contact phone: 9224 0317

You can read about Acomplia much more here:Acomplia
Zimulti Acomlia Rimonabant